Shares of Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) dropped 5.5% during trading on Tuesday . The company traded as low as $2.70 and last traded at $2.74. Approximately 996,975 shares were traded during trading, a decline of 47% from the average daily volume of 1,890,213 shares. The stock had previously closed at $2.90.

Separately, ValuEngine upgraded shares of Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 11th.

The company has a market cap of $191.51, a P/E ratio of -13.70 and a beta of 0.51.

An institutional investor recently bought a new position in Ampio Pharmaceuticals stock. Creative Planning bought a new position in Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 28,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $116,000.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with's FREE daily email newsletter.